Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Enrollment Complete
Learn More
Press Releases
Nov 24, 2022
Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Read More
Nov 14, 2022
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
Read More
